IrsiCaixa’s scientific activity search engine

Strategic line

Other diseases

Keywords: antivirals, cancer, co-infection, drugs, hepatitis, infectious disease, papilloma, vaccines
Strategic line

Immunopathogenesis

Keywords: ageing, drugs, ebola, immune system, immunosenescence, infectious diseases, inflammation, microbiome...
Strategic line

Microbiome

Keywords: ageing, bacteria, eradication, functional cure, immune system, infectious diseases, inflammation, in...
Strategic line

New treatments and resistance to antiretrovirals

Keywords: resistance
Strategic line

Prevention, eradication and functional cure

Keywords: HTI, therapeutic vaccine, preventive vaccine, monoclonal antibodies, latency reactivation, reservoi...
Clinical research

An Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of ABX464 in HIV-1 Seronegative and Seropositive Adults | AbiVax 005
Clinical research

Assaig clínic de fase I, randomitzat, doble cec, controlat amb placebo per avaluar la seguretat, la tolerància i la immunogenicitat de les vacunes DNA.HTI administrades en combinació amb MVA.HTI en 15 pacients VIH positius diagnosticats i tractats de forma precoç | Aelix-002

Participating entities: Hospital Germans Trias i Pujol -Fundació Lluita contra la Sida i Institut de Recerca de la Sida IrsiCaixa- de Badalona, Espanya

Clinical research

Assaig clínic per avaluar l’efecte del durvalumab (MEDI4736) en pacients VIH-positius amb tumors sòlids avançats | Durvast
Research group

Viral Immune Evasion and Vaccines (VIRIEVAC)

Main researcher: Julia García Prado
Research group

Microbial Genomics

Main researcher: Roger Paredes

Subscribe to our newsletter

Back to Top
Irsi Caixa

Promoted by:

'La Caixa' Foundation Generalitat de Catalunya - Departament de Salut

 

HR Excellence in Research

Member of:

Cerca

In cooperation with: